BCRP Inhibition: from Data Collection to Ligand‐Based Modeling
暂无分享,去创建一个
[1] Michael Dean,et al. New inhibitors of ABCG2 identified by high-throughput screening , 2007, Molecular Cancer Therapeutics.
[2] Qingcheng Mao,et al. Role of the breast cancer resistance protein (ABCG2) in drug transport , 2005, The AAPS Journal.
[3] E. LaVoie,et al. Synthesis of N-substituted 5-[2-(N-alkylamino)ethyl]dibenzo[c,h][1,6]naphthyridines as novel topoisomerase I-targeting antitumor agents. , 2008, Bioorganic & medicinal chemistry.
[4] Francesca Borrelli,et al. Nonprenylated rotenoids, a new class of potent breast cancer resistance protein inhibitors. , 2007, Journal of medicinal chemistry.
[5] Marilyn E. Morris,et al. Structure–Activity Relationships and Quantitative Structure–Activity Relationships for Breast Cancer Resistance Protein (ABCG2) , 2009, The AAPS Journal.
[6] Sean Ekins,et al. Precompetitive preclinical ADME/Tox data: set it free on the web to facilitate computational model building and assist drug development. , 2010, Lab on a chip.
[7] Michael Wiese,et al. Structure-activity relationships of flavonoids as inhibitors of breast cancer resistance protein (BCRP). , 2011, Bioorganic & medicinal chemistry.
[8] C. Hrycyna,et al. Multidrug resistance and cancer: the role of the human ABC transporter ABCG2. , 2002, Current protein & peptide science.
[9] S. Hladky,et al. Interaction of the breast cancer resistance protein with plant polyphenols. , 2004, Biochemical and biophysical research communications.
[10] X. Ronot,et al. Piperazinobenzopyranones and phenalkylaminobenzopyranones: potent inhibitors of breast cancer resistance protein (ABCG2). , 2005, Journal of medicinal chemistry.
[12] Ulf Norinder,et al. Identification of Novel Specific and General Inhibitors of the Three Major Human ATP-Binding Cassette Transporters P-gp, BCRP and MRP2 Among Registered Drugs , 2009, Pharmaceutical Research.
[13] T. Litman,et al. Molecular cloning of cDNAs which are highly overexpressed in mitoxantrone-resistant cells: demonstration of homology to ABC transport genes. , 1999, Cancer research.
[14] F. Berardi,et al. Synthesis and biological evaluation of (hetero)arylmethyloxy- and arylmethylamine-phenyl derivatives as potent P-glycoprotein modulating agents. , 2008, Journal of medicinal chemistry.
[15] L. Doyle,et al. A multidrug resistance transporter from human MCF-7 breast cancer cells. , 1998, Proceedings of the National Academy of Sciences of the United States of America.
[16] T. Ishikawa,et al. Cellular Phototoxicity Evoked Through the Inhibition of Human ABC Transporter ABCG2 by Cyclin-dependent Kinase Inhibitors In vitro , 2009, Pharmaceutical Research.
[17] A. Buschauer,et al. Solid phase synthesis of tariquidar-related modulators of ABC transporters preferring breast cancer resistance protein (ABCG2). , 2011, Bioorganic & medicinal chemistry letters.
[18] Veronika F. S. Pape,et al. Investigation of chalcones and benzochalcones as inhibitors of breast cancer resistance protein. , 2012, Bioorganic & medicinal chemistry.
[19] Tingjun Hou,et al. New Use for an Old Drug: Inhibiting ABCG2 with Sorafenib , 2012, Molecular Cancer Therapeutics.
[20] Ulf Norinder,et al. A Global Drug Inhibition Pattern for the Human ATP-Binding Cassette Transporter Breast Cancer Resistance Protein (ABCG2) , 2007, Journal of Pharmacology and Experimental Therapeutics.
[21] H. V. van Veen,et al. Metabolites of ginsenosides as novel BCRP inhibitors. , 2006, Biochemical and biophysical research communications.
[22] M. Morris,et al. Flavonoids are inhibitors of breast cancer resistance protein (ABCG2)-mediated transport. , 2004, Molecular pharmacology.
[23] W. Haefeli,et al. Modulation of human BCRP (ABCG2) activity by anti-HIV drugs. , 2006, The Journal of antimicrobial chemotherapy.
[24] G. Giannini,et al. E-ring-modified 7-oxyiminomethyl camptothecins: Synthesis and preliminary in vitro and in vivo biological evaluation. , 2008, Bioorganic & medicinal chemistry letters.
[25] W. Haefeli,et al. Interaction Potential of Etravirine with Drug Transporters Assessed In Vitro , 2010, Antimicrobial Agents and Chemotherapy.
[26] A. Tropsha,et al. Human Intestinal Transporter Database: QSAR Modeling and Virtual Profiling of Drug Uptake, Efflux and Interactions , 2013, Pharmaceutical Research.
[27] A. di Pietro,et al. Potent and fully noncompetitive peptidomimetic inhibitor of multidrug resistance P-glycoprotein. , 2010, Journal of medicinal chemistry.
[28] Á. Ravelo,et al. Bis-pyranobenzoquinones as a new family of reversal agents of the multidrug resistance phenotype mediated by P-glycoprotein in mammalian cells and the protozoan parasite Leishmania. , 2008, Journal of medicinal chemistry.
[29] Y. Sugimoto,et al. Flavonoids inhibit breast cancer resistance protein-mediated drug resistance: transporter specificity and structure–activity relationship , 2007, Cancer Chemotherapy and Pharmacology.
[30] Vincenzo,et al. A human placenta-specific ATP-binding cassette gene (ABCP) on chromosome 4q22 that is involved in multidrug resistance. , 1998, Cancer research.
[31] M. Go,et al. Functionalized chalcones as selective inhibitors of P-glycoprotein and breast cancer resistance protein. , 2008, Bioorganic & medicinal chemistry.
[32] Curtis J Henrich,et al. Flavonoids from eight tropical plant species that inhibit the multidrug resistance transporter ABCG2. , 2011, Journal of natural products.
[33] Y. Sugimoto,et al. Phytoestrogens/Flavonoids Reverse Breast Cancer Resistance Protein/ABCG2-Mediated Multidrug Resistance , 2004, Cancer Research.
[34] Stephan Kopp,et al. Multispecificity of Drug Transporters: Probing Inhibitor Selectivity for the Human Drug Efflux Transporters ABCB1 and ABCG2 , 2007, ChemMedChem.
[35] Peter W Swaan,et al. Identification of novel breast cancer resistance protein (BCRP) inhibitors by virtual screening. , 2013, Molecular pharmaceutics.
[36] Hikaru Saito,et al. Molecular modeling of new camptothecin analogues to circumvent ABCG2-mediated drug resistance in cancer. , 2006, Cancer letters.
[37] J. Allen,et al. Inhibition of BCRP-mediated drug efflux by fumitremorgin-type indolyl diketopiperazines. , 2001, Bioorganic & medicinal chemistry letters.
[38] G. Bemis,et al. The properties of known drugs. 1. Molecular frameworks. , 1996, Journal of medicinal chemistry.
[39] Julien Boccard,et al. Breast cancer resistance protein (BCRP/ABCG2): new inhibitors and QSAR studies by a 3D linear solvation energy approach. , 2009, European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences.
[40] J. Allen,et al. The multidrug transporter ABCG2 (BCRP) is inhibited by plant‐derived cannabinoids , 2007, British journal of pharmacology.
[41] T. Ishikawa,et al. Novel camptothecin analogues that circumvent ABCG2‐associated drug resistance in human tumor cells , 2004, International journal of cancer.
[42] M. Wiese,et al. Synthesis and Quantitative Structure–Activity Relationships of Selective BCRP Inhibitors , 2013, ChemMedChem.
[43] Shuzhong Zhang,et al. Structure activity relationships and quantitative structure activity relationships for the flavonoid-mediated inhibition of breast cancer resistance protein. , 2005, Biochemical pharmacology.
[44] Michael Wiese,et al. Structure-activity relationships of new inhibitors of breast cancer resistance protein (ABCG2). , 2008, Bioorganic & medicinal chemistry.
[45] T. Tsuruo,et al. Reversal of breast cancer resistance protein-mediated drug resistance by estrogen antagonists and agonists. , 2003, Molecular cancer therapeutics.
[46] Francisco Gamarro,et al. Flavonoid structure-activity studies identify 6-prenylchrysin and tectochrysin as potent and specific inhibitors of breast cancer resistance protein ABCG2. , 2005, Cancer research.
[47] J. Donovan,et al. Antipsychotic drugs inhibit the function of breast cancer resistance protein. , 2008, Basic & clinical pharmacology & toxicology.
[48] M. Wiese,et al. Novel lead for potent inhibitors of breast cancer resistance protein (BCRP). , 2010, Bioorganic & medicinal chemistry letters.
[49] Chris Morley,et al. Open Babel: An open chemical toolbox , 2011, J. Cheminformatics.
[50] M. Wiese,et al. 4-Substituted-2-phenylquinazolines as inhibitors of BCRP. , 2012, Bioorganic & medicinal chemistry letters.
[51] Pekka Tiikkainen,et al. Estimating Error Rates in Bioactivity Databases , 2013, J. Chem. Inf. Model..
[52] Zhe-Sheng Chen,et al. Inhibition of c-Kit, VEGFR-2 (KDR), and ABCG2 by analogues of OSI-930. , 2011, Bioorganic & medicinal chemistry letters.
[53] A. di Pietro,et al. Acridone derivatives: design, synthesis, and inhibition of breast cancer resistance protein ABCG2. , 2007, Bioorganic & medicinal chemistry.
[54] Hiroyuki Hirano,et al. A New Strategy of High-Speed Screening and Quantitative Structure-Activity Relationship Analysis to Evaluate Human ATP-Binding Cassette Transporter ABCG2-Drug Interactions , 2006, Journal of Pharmacology and Experimental Therapeutics.
[55] K. Gustafson,et al. Synthesis and structure-activity relationship of botryllamides that block the ABCG2 multidrug transporter. , 2010, Bioorganic & medicinal chemistry letters.
[56] F. Berardi,et al. 2-[(3-Methoxyphenylethyl)phenoxy]-based ABCB1 inhibitors: effect of different basic side-chains on their biological properties. , 2008, Journal of medicinal chemistry.
[57] E. LaVoie,et al. 12-Substituted 2,3-dimethoxy-8,9-methylenedioxybenzo[i]phenanthridines as novel topoisomerase I-targeting antitumor agents. , 2009, Bioorganic & medicinal chemistry.
[58] Christin Müller,et al. Potent and selective inhibitors of breast cancer resistance protein (ABCG2) derived from the p-glycoprotein (ABCB1) modulator tariquidar. , 2009, Journal of medicinal chemistry.